Efficacy and Safety Results of the Afatinib Expanded Access Program.

about

Efficacy and Safety Results of the Afatinib Expanded Access Program.

Item

http://www.wikidata.org/entity/Q52763503

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Efficacy and Safety Results of the Afatinib Expanded Access Program.

@en

Efficacy and Safety Results of the Afatinib Expanded Access Program.

@nl

type

Item

label

Efficacy and Safety Results of the Afatinib Expanded Access Program.

@en

Efficacy and Safety Results of the Afatinib Expanded Access Program.

@nl

prefLabel

Efficacy and Safety Results of the Afatinib Expanded Access Program.

@en

Efficacy and Safety Results of the Afatinib Expanded Access Program.

@nl

P1476

Efficacy and Safety Results of the Afatinib Expanded Access Program.

@en

P2093

Agnieszka Cseh

http://www.w3.org/2001/XMLSchema#string

Alexander I Spira

http://www.w3.org/2001/XMLSchema#string

Balazs Halmos

http://www.w3.org/2001/XMLSchema#string

Edward S Kim

http://www.w3.org/2001/XMLSchema#string

Gudrun Wallenstein

http://www.w3.org/2001/XMLSchema#string

Ingrid F Kohut

http://www.w3.org/2001/XMLSchema#string

John McKay

http://www.w3.org/2001/XMLSchema#string

Kathryn F Mileham

http://www.w3.org/2001/XMLSchema#string

Regan D Rostorfer

http://www.w3.org/2001/XMLSchema#string

Taral Patel

http://www.w3.org/2001/XMLSchema#string

P2860

Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial.

Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials.

Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial.

Efficacy of the irreversible ErbB family blocker afatinib in epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)-pretreated non-small-cell lung cancer patients with brain metastases or leptomeningeal disease.

P2888

s40487-017-0043-5

P304

103-110

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S40487-017-0043-5

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-04-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28680960

http://www.w3.org/2001/XMLSchema#string

P932

5488108

http://www.w3.org/2001/XMLSchema#string